February 2015 Issue of The Medicine Maker

Can pharma get over its IP anxiety and embrace meaningful partnerships?

Scientists in California have ‘unboiled’ an egg – with some interesting implications for biopharma...

Research into rare diseases is on the rise, but are prices sustainable?

Research into rare diseases is on the rise, but are prices sustainable?

Could the Pfizer–Hospira deal be a stepping stone to a company split?

Is early and regular dialogue with regulatory agencies the key to success for smaller companies?

Only you have the answer. Nominate now.

Pharma companies look to new genetic screening technology to enhance drug discovery.

A ‘robot scientist’, capable of independently carrying out drug screening research, has been developed by UK researchers.

Can nanotechnology pick up where personalized medicine leaves off?

A classification system could make the R&D–manufacturing interface much easier to navigate.

Women’s health used to be considered solely in terms of maternal and reproductive health. Not anymore.

Cutting corners in process development will come back to haunt you – especially in the biopharmaceutical arena.

Pushing for cleaner, greener manufacturing is not only good for the planet, it’s great for business.

A multimillion Euro project is pushing green chemistry forward in Europe. The secret of its success? Collaboration, collaboration, collaboration!

The field of green chemistry is concerned with minimization of waste and avoidance of toxic and hazardous substances in pharmaceutical products.

Green thinking sometimes seems a long way off for those of us in medicinal chemistry

At Genentech, a member of the Roche Group, the Green BioPharma program aims to bring sustainability into R&D labs.

Climate change, health challenges, and resource inefficiencies or shortages are very high on the agenda of societies around the world. And rightly so

Global healthcare company GlaxoSmithKline (GSK) has pledged to be carbon neutral by 2050.

With regulators looking for more differentiation between tablets, we must be bolder with solid dosage designs.

Our ‘dynamic flowsheet model’ links API purification and processing with downstream tablet manufacturing to provide better control of the process variables

With only one approved drug and many failures, the cancer vaccine field has lost some of its shine.

Sitting Down With… James Christie, Project Director for Manufacturing, Association of the British Pharmaceutical Industry (ABPI), London, UK.